骨康胶囊与双氯芬酸钠肠溶片联合应用致药物性肝损伤1例

A Case of Drug-induced Liver Injury Caused by the Combined Application of Gukang Capsules and Diclofenac Sodium Enteric-coated Tablets

目的探讨骨康胶囊与双氯芬酸钠肠溶片导致药物性肝损伤的风险,为临床合理用药提供参考。方法分析该院2019年6月13日1例药物性肝损伤患者的病情和用药史,结合指南和文献判断是否为骨康胶囊与双氯芬酸钠肠溶片联用导致的药物不良反应,并协助医师制定治疗方案。结果通过药物不良反应关联性评价,该病例为骨康胶囊与双氯芬酸钠肠溶片联用导致的药物性肝损伤,患者经治疗后肝功能恢复。结论骨康胶囊与双氯芬酸钠肠溶片联用增加药物性肝损伤的风险,建议谨慎联用。

Objective To investigate the risk of drug-induced liver injury caused by Gukang capsules and diclofenac sodium enteric-coated tablets,and to provide references for clinical rational drug use.Methods The analyzed the condition and medication history of a patient with drug-induced liver injury in the hospital on June 13,2019,combined with the guidelines and literature to determine whether it was an adverse drug reaction caused by the combination of Gukang capsules and diclofenac sodium enteric-coated tablets,and assisted The doctor makes a treatment plan.Results Through the evaluation of the association of adverse drug reactions,this case was a drug-induced liver injury caused by the combination of Gukang capsules and diclofenac sodium enteric-coated tablets.The patient's liver function recovered after treatment.Conclusion The combined use of Gukang capsules and diclofenac sodium enteric-coated tablets increases the risk of drug-induced liver injury.It is recommended to use the combination with caution.